In this study, we present a patient with ITP who developed recurrent myocardial infarction and intense thrombus in the stent after increasing the eltrombopag dose.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Immune thrombocytopenia (ITP) is an acquired disorder caused by immune-mediated attack, enhanced clearance, and insufficient compensatory production of platelets.
📊
Key Findings & Data:Historically, ITP treatment strategies have suppressed platelet destruction with glucocorticoids, intravenous immune globulin (IVIG), cytotoxic agents, and splenectomy (1).
💡
Conclusion & Impact:In this study, we present a patient with ITP who developed recurrent myocardial infarction and intense thrombus in the stent after increasing the eltrombopag dose.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Özet
Immune thrombocytopenia (ITP) is an acquired disorder caused by immune-mediated attack, enhanced clearance, and insufficient compensatory production of platelets. Historically, ITP treatment strategies have suppressed platelet destruction with glucocorticoids, intravenous immune globulin (IVIG), cytotoxic agents, and splenectomy (1). Eltrombopag is an oral nonpeptide thrombopoietin receptor agonist (TPO-RA) approved for use in several countries for the treatment of ITP with insufficient response to corticosteroids, immunoglobulins, or splenectomy. In this study, we present a patient with ITP who developed recurrent myocardial infarction and intense thrombus in the stent after increasing the eltrombopag dose.
🔖
Cite This Article
ÖZGÜNOĞLU, E. C., BAYAR, N., ARSLAN, Ş., ERSOYSAL, M. R., AVCI, R. (2021). Is the increase in eltrombopag dose cause of myocardial infarction?. The Anatolian Journal of Cardiology, Cilt: 25 - Sayı: 7, 520–521. https://ajindex.com/articles/365137
Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA; American Society of Hematology. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011; 117: 4190-207. [Crossref] 2. Haselboeck J, Kaider A, Pabinger I, Panzer S. Function of eltrombopag-induced platelets compared to platelets from control patients with immune thrombocytopenia. Thromb Haemost 2013; 109: 676-83. [Crossref] 3. Bussel JB, Cheng G, Saleh MN, Mayer B, Vasey SY, Brainsky A. Incidence of Thromboembolic Events Across Eltrombopag Clinical Trials In Chronic Immune Thrombocytopenia (ITP). Blood 2010; 116: A70. [Crossref] 4. Teichman J, Taher A, Hashi A, Bagai A, Sholzberg M. A sticky situation: myocardial infarction in a young woman with immune thrombocytopenia on eltrombopag and a history of mediastinal radiation. J Thromb Thrombolysis 2018; 45: 192-5. [Crossref] 5. Sert S, Özdil H, Sünbül M. Acute Myocardial Infarction Due to Eltrombopag Therapy in a Patient with Immune Thrombocytopenic Purpura. Turk J Haematol 2017; 34: 107-8. [Crossref] 6. Gunes H, Kivrak T. Eltrombopag Induced Thrombosis: A Case with Acute Myocardial Infarction. Curr Drug Saf 2016; 11: 174-6. [Crossref] 7. Andic N, Gunduz E, Akay OM, Şahin D, Teke HÜ. Cardiac and pulmonary thrombosis during multidrug treatment in an idiopathic thrombocytopenic purpura patient. Platelets 2014; 25: 69-70. [Crossref] 8. Koklu E, Kus G, Yuksel IO, Kucukseymen S, Arslan S. Successful thrombolytic therapy for ST-elevation acute myocardial infarction in a patient with immune thrombocytopenic purpura. Am J Emerg Med 2016; 34: 345.e1-3. [Crossref] 9. Satoh T, Saotome M, Suwa K, Ohtani H, Nagata Y, Ono T, et al. Recurrent Coronary Thrombus in a Patient with Chronic Immune Thrombocytopenia with Treatment Using Eltrombopag. Case Rep Cardiol 2019; 2019: 2756319. [Crossref] 10. Garbe E, Andersohn F, Bronder E, Salama A, Klimpel A, Thomae M, et al. Drug-induced immune thrombocytopaenia: results from the Berlin Case-Control Surveillance Study. Eur J Clin Pharmacol 2012; 68: 821-32. [Crossref]